Inactivated Influenza Vaccine

Vaccine Description	As influenza products differ in approved age ranges and dosages, it is imperative to verify with the manufacturer package insert. • Quadrivalent: Afluria® (IIV4), Fluarix® (IIV4), FluLaval® (IIV4), and Fluzone® (IIV4) • Cell Cultured-Based: Flucelvax® (cclIV4) The tip cap and rubber plunger of needleless prefilled syringes may contain dry natural latex rubber (see package inserts); Thimerosal may be found in multi-dose vials. Preservative-free forms are available. Some brands contain minute quantities of egg protein.			
Dose & Route	Approved age range		Trade Name	Dose/Route
	6 months to 35 months		Fluzone® (IIV4)	0.25 ml or 0.50 ml IM* (See Special Considerations)
			Afluria® (IIV4)	0.25 mL IM*
	≥ 6 months		Fluarix® (IIV4)	0.5 mL IM*
			Flulaval® (IIV4)	0.5 mL IM*
			Flucelvax® (ccllV4)	0.5 mL IM*
	≥ 3 years		Fluzone® (IIV4)	0.5 mL IM*
			Afluria® (IIV4)	0.5 mL IM*
	*Precaution: hemophilia, thrombocytopenia, and anticoagulation therapy			
	IIV4=egg based trivalent/quadrivalent inactivated influenza vaccine (injectable) ccIV4=cell cultured, quadrivalent inactivated influenza vaccine RIV4=quadrivalent recombinant hemagglutinin influenza vaccine			
Indications	All people 6 months of age and older			
Administration Schedule	AGE	DOSE	Recommended Interval	
6 months through 8 years of age	6 to 35 months	Afluria® and Fluzone® 0.25 mL	First-time vaccinees or those who have not received 2 or more doses since 2010: Give 2 doses separated by at least 4 weeks. Any combination of influenza vaccine may be used to complete the series.	
	≥ 6 months	Flulaval® 0.5 mL		
	≥ 3 years	0.5 mL		
≥ 9 years of age	≥ 9 years	One dose 0.5 mL	Annually	

Inactivated Influenza Vaccine

(Continued)

All children and teens 6 months of age and older, who do not have a contraindication, should receive the age-appropriate formulation of inactivated influenza vaccine (IIV) each year. (Note: healthy, non-pregnant persons 2 through 49 years of age without high risk health conditions can receive IIV or LAIV*). A second dose of influenza vaccine is recommended 4 weeks or more after the first dose for children age 6 months through 8 years if they have not received 2 doses in previous years (not necessarily in the same season). Do not give influenza vaccine to a child or adolescent who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components (for a list of vaccine components, refer to the manufacturer's package insert (www.health.milfluresourcecenter) or oto: www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf. Precautions Moderate or severe acute illness with or without fever			
experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components (for a list of vaccine components, refer to the manufacturer's package insert (www.health.mil/fluresourcecenter) or go to: www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf. Precautions • Moderate or severe acute illness with or without fever • History of Guillain-Barré syndrome within 6 weeks of a previous influenza vaccination • Immunization providers should check Food and Drug Administration-approved seasonal influenza vaccines prescribing information for the most complete and up-to-date information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S. licensed vaccines are available at: www.health.mil/fluresourcecenter. • Afluria® is licensed for administration by jet injector for persons aged 18 through 64 years only. • Once the stopper of the multi-dose vial has been pierced, the vial must be discarded either at the expiration date on the vial or within 28 days — see the package insert for specific guidance. • It is important to review CDC/ACIP guidelines for LAIV use before each flu season. • The FluLaval® (IIV4) 0.5mL dose is the same for adults and children. • Children who are immunocompromised may have reduced immune response. • Fluzone for ages 6-35 months old: The schedule can be completed as two 0.25-mL doses ≥4 weeks apart, two 0.50mL doses ≥4 weeks apart, two 0.50mL doses ≥4 weeks apart, or any combination of 2 doses (either 0.25 mL or 0.50 mL) administered ≥4 weeks apart.	Indications	have a contraindication, should receive the age-appropriate formulation of inactivated influenza vaccine (IIV) each year. (Note: healthy, non-pregnant persons 2 through 49 years of age without high risk health conditions can receive IIV or LAIV*). • A second dose of influenza vaccine is recommended 4 weeks or more after the first dose for children age 6 months through 8 years if they have not received 2 doses in previous years (not	
History of Guillain-Barré syndrome within 6 weeks of a previous influenza vaccination Special Considerations	Contraindications	experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components (for a list of vaccine components, refer to the manufacturer's package insert (www.health.mil/fluresourcecenter) or go to: www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-	
Considerations Administration-approved seasonal influenza vaccines prescribing information for the most complete and up-to-date information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S. licensed vaccines are available at: www.health.mil/fluresourcecenter. Afluria® is licensed for administration by jet injector for persons aged 18 through 64 years only. Once the stopper of the multi-dose vial has been pierced, the vial must be discarded either at the expiration date on the vial or within 28 days — see the package insert for specific guidance. It is important to review CDC/ACIP guidelines for LAIV use before each flu season. The FluLaval® (IIV4) 0.5mL dose is the same for adults and children. Children who are immunocompromised may have reduced immune response. Fluzone for ages 6-35 months old: The schedule can be completed as two 0.25-mL doses ≥4 weeks apart, two 0.50mL doses ≥4 weeks apart, two 0.50mL doses ≥4 weeks apart.	Precautions	History of Guillain-Barré syndrome within 6 weeks of a previous	
		Immunization providers should check Food and Drug Administration-approved seasonal influenza vaccines prescribing information for the most complete and up-to-date information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S. licensed vaccines are available at: www.health.mil/fluresourcecenter. Afluria® is licensed for administration by jet injector for persons aged 18 through 64 years only. Once the stopper of the multi-dose vial has been pierced, the vial must be discarded either at the expiration date on the vial owithin 28 days — see the package insert for specific guidance. It is important to review CDC/ACIP guidelines for LAIV use before each flu season. The FluLaval® (IIV4) 0.5mL dose is the same for adults and children. Children who are immunocompromised may have reduced immune response. Fluzone for ages 6-35 months old: The schedule can be completed as two 0.25-mL doses ≥4 weeks apart, two 0.50mL doses ≥4 weeks apart, or any combination of 2 doses (either 0.25 mL or 0.50 mL) administered ≥4 weeks apart.	

VIS: http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.html Additional education may be found at www.health.mil/flu